New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
07:16 EDTSGEN, ECYTEndocyte added to Top Picks list; Seattle Genetics removed at Credit Suisse
Credit Suisse added Endocyte to the Top Picks list based on vintafolide regulatory and clinical events over the next 12 months, a strong cash position, and asset ownership, among other reasons.
News For ECYT;SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
06:32 EDTSGENAtara Biotherapeutics appoints Eric Dobmeier to board
Atara Biotherapeutics (ATRA) announced that Eric Dobmeier has joined its board. Dobmeier is currently the COO of Seattle Genetics (SGEN).
March 23, 2015
08:22 EDTSGENEditorial on Seattle Genetics AETHERA was positive, says RBC Capital
RBC Capital believes that the Lancet editorial on Seattle Genetics' AETHERA was positive, and the firm expects the drug's label to expand. However, the firm warns that for further upside Seattle Genetics needs one or more programs targeting unmet need with clearly delineated paths to approval. The firm keeps a $50 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use